Jubilant Generics' Roorkee facility determined official action indicated

Jubilant Pharmova Limited's wholly owned subsidiary Jubilant Pharma Limited, today announced that its subsidiary Jubilant Generics Limited (JGL) ('Company') received a communication from the USFDA through which the latter intimated that pursuant to its July-Aug 2022 audit of JGL's Solid Dosage Manufacturing facility at Roorkee it has determined inspection classification of the facility as "official action indicated".

The Company currently supplies one product to US market that contributes low-single digit revenue to Jubilant Pharmova revenues.

The Company has been continuously cooperating with the USFDA and will undertake all necessary steps to resolve regulatory status at the Roorkee facility.

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 371.10 as compared to the previous close of Rs. 348.50. The total number of shares traded during the day was 94278 in over 3851 trades.

The stock hit an intraday high of Rs. 377.00 and intraday low of 349.40. The net turnover during the day was Rs. 34531168.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 JubilantPharma JubilantOrganics USFDA OfficialActionIndicated